A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
Sponsor: Eli Lilly and Company
A observational or N/A phase clinical study on Obesity and Overweight, this trial is actively recruiting participants. The trial is conducted by Eli Lilly and Company and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Apr 18, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
First recorded
Dec 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Alzira, Spain , Ansan-si, South Korea , Aurora, United States , Austin, United States , Bangalore, India , Barcelona, Spain , Barcelona, Spain , Beijing, China , Beijing, China and 149 more locations